ARS Pharmaceuticals (SPRY) Profit After Tax (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Profit After Tax data on file, last reported at -$60.6 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 78.6% year-over-year to -$60.6 million; the trailing twelve-month figure through Mar 2026 stood at -$198.1 million (down 1219.59% YoY), and the FY2025 full-year result was -$171.4 million, down 2198.09% from the prior year.
• Profit After Tax retreated to -$60.6 million in Q1 2026, from -$41.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $50.1 million in Q4 2024 to a low of -$60.6 million in Q1 2026.
• A 5-year average of -$18.4 million and a median of -$14.9 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax surged 799.01% in 2024 and tumbled 258.95% in 2025, its largest moves.
• Tracing SPRY's Profit After Tax over 5 years: stood at -$14.4 million in 2022, then surged by 50.32% to -$7.2 million in 2023, then surged by 799.01% to $50.1 million in 2024, then plunged by 182.66% to -$41.4 million in 2025, then sank by 46.35% to -$60.6 million in 2026.
• Business Quant data shows SPRY's Profit After Tax at -$60.6 million in Q1 2026, -$41.4 million in Q4 2025, and -$51.1 million in Q3 2025.